Bernstein analyst lifts ASML's price target to $1,911, citing a buying opportunity after recent pullback. The chip equipment giant's record Q4 orders and updated guidance signal confidence in the AI-driven semiconductor upcycle.
Despite recent sharp declines triggered by Fed nomination news, JPMorgan analysts reaffirm a bullish $6,300 per ounce gold target for 2026, citing resilient demand from central banks and investors.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
As Palantir Technologies prepares to report Q4 results, soaring demand for its AI platform collides with sky-high valuations, leaving investors to weigh robust growth against bubble fears.
In an unusual acquisition within the ETF space, the investment arm behind former President Donald Trump's social media platform is set to purchase the conservative-themed 'God Bless America' ETF, significantly expanding its asset base and adding active management to its lineup.
Franklin Templeton has launched the Templeton Emerging Markets Debt ETF (TEMD), aiming to give investors targeted exposure to both hard and local currency debt from developing economies, capitalizing on the asset class's recent strong performance.
New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
Morgan Stanley's top strategist argues that recent U.S. trade shifts have prompted nations worldwide to reassess and leverage their own economic strengths, creating a multi-year investment opportunity in a more multipolar global order.
CNBC's Jim Cramer endorsed Carrier Global Corp. (NYSE:CARR) on his recent show, praising CEO Dave Gitlin's leadership and strategic acquisition. He recommended investors buy the stock for the long term, citing confidence in the company's positioning within the climate solutions sector.
CNBC's Jim Cramer expressed reservations about aviation services provider AAR Corp., highlighting its 15% gross yield as a potential red flag for investors during a recent market analysis segment.
CNBC's Jim Cramer reaffirmed his bullish stance on Rio Tinto, highlighting the mining giant's role as a strategic hedge against geopolitical and economic volatility during the show's Lightning Round.
CNBC's Jim Cramer highlighted International Business Machines Corp. (IBM) as a standout AI investment with a relatively modest valuation, following a robust quarterly report that sent shares soaring.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
AbbVie's stock presents a complex picture for investors, with recent mixed performance contrasting sharply with its robust multi-year returns. As shares trade below consensus targets, the market weighs near-term headwinds against the pharmaceutical giant's proven track record and pipeline potential.
The Federal Reserve left interest rates unchanged, signaling confidence in a solid economy while inflation remains above target. The decision sets up a continued clash with a President demanding deeper cuts.
Dropbox shares have faced significant pressure over the past year, declining roughly 20% and raising questions about its long-term growth trajectory. As the stock trades below key fair value estimates, investors are divided on whether this represents a buying opportunity or reflects deeper challenges in the competitive cloud storage market.
In a strategic pivot, Bed Bath & Beyond acquires Tokens.com, aiming to launch a platform for tokenizing real-world assets like real estate and securities, with shares rising on the news.
As the ASX braces for a turbulent February amid rate hike fears, a closer look reveals resilient micro-caps with unique value propositions. We analyze three sub-$150M companies—from healthcare tech to critical minerals—that are navigating the volatility with strong balance sheets and niche market positions.
